LianBio Raises $310 Million to Bring Novel Medications to China

LianBio, a Princeton-Shanghai company, raised an impressive $310 million in an oversubscribed crossover financing from a large group of US and China investors. The funding follows LianBio's founding and initial financing provided by Perceptive Advisors. LianBio is focused on bringing novel drugs to China and major Asian markets. Perceptive formed the company to become involved in China's vibrant biopharma ecosystem. In its 21 years of operation, Perceptive has made investments in 150 public and 80 private biopharmas. So far, LianBio's in-licensed assets have come from Perceptive portfolio companies. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.